These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34237488)

  • 21. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.
    Burgess EF; Livasy C; Hartman A; Robinson MM; Symanowski J; Naso C; Doherty S; Guerrieri R; Riggs S; Grigg CM; Clark PE; Raghavan D
    Urol Oncol; 2019 May; 37(5):299.e19-299.e25. PubMed ID: 30660491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
    Liu X; Guo CY; Tou FF; Wen XM; Kuang YK; Zhu Q; Hu H
    Int J Cancer; 2020 Jul; 147(1):116-127. PubMed ID: 31633798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer.
    Wei XL; Luo X; Sheng H; Wang Y; Chen DL; Li JN; Wang FH; Xu RH
    J Transl Med; 2020 Dec; 18(1):475. PubMed ID: 33308232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
    Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
    Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.
    Tanaka T; Kutomi G; Kajiwara T; Kukita K; Kochin V; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T; Okamoto Y; Hirata K; Sato N; Tamura Y
    Oncotarget; 2017 Apr; 8(15):24706-24718. PubMed ID: 28160557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
    Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
    Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.
    Houssami N; Macaskill P; Balleine RL; Bilous M; Pegram MD
    Breast Cancer Res Treat; 2011 Oct; 129(3):659-74. PubMed ID: 21698410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
    Bertucci F; Gonçalves A
    Curr Oncol Rep; 2017 Aug; 19(10):64. PubMed ID: 28799073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
    Hirakata T; Fujii T; Kurozumi S; Katayama A; Honda C; Yanai K; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Kaira K; Oyama T; Shirabe K
    Breast Cancer Res Treat; 2020 Jun; 181(2):331-338. PubMed ID: 32253685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
    Engerud H; Berg HF; Myrvold M; Halle MK; Bjorge L; Haldorsen IS; Hoivik EA; Trovik J; Krakstad C
    Gynecol Oncol; 2020 Apr; 157(1):260-267. PubMed ID: 31973911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy.
    Wang HB; Yao H; Li CS; Liang LX; Zhang Y; Chen YX; Fang JY; Xu J
    J Dig Dis; 2017 Oct; 18(10):574-581. PubMed ID: 28851046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters.
    Yuan C; Liu Z; Yu Q; Wang X; Bian M; Yu Z; Yu J
    Sci Rep; 2019 Oct; 9(1):14356. PubMed ID: 31591439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
    Shen X; Zhao B
    BMJ; 2018 Sep; 362():k3529. PubMed ID: 30201790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
    Passiglia F; Bronte G; Bazan V; Natoli C; Rizzo S; Galvano A; Listì A; Cicero G; Rolfo C; Santini D; Russo A
    Oncotarget; 2016 Apr; 7(15):19738-47. PubMed ID: 26918451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
    Huang W; Ran R; Shao B; Li H
    Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
    Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.